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Abstract
Background: Placental site trophoblastic tumor (PSTT) is a rare and unique form of gestational
trophoblastic disease (GTD). This tumor represents a neoplastic transformation of intermediate
trophoblastic cells. We document a case of long term remission in a patient with metastatic PSTT.
Case presentaion: A 27-year-old patient with metastatic PSTT was treated with combination
therapy (chemotherapy and surgery). Patient is alive after 10 years without any evidence of
recurrence. Literature on PSTT was searched using Medline and cross references, and pertinent
articles were reviewed.
Conclusion: With surgery and chemotherapy it is possible to achieve long-term remission in
metastatic PSTT. Only a handful of previously reported cases with prolonged remission had been
treated with the described combined chemotherapy and surgical approach. We suggest that this
approach may be recommended for metastatic PSTT.
Background
Placental Site Trophoblastic Tumor (PSTT) is a rare form
of gestational trophoblastic disease (GTD) and was
described by Kurman et al [1]. In 1976, it was thought to
be an exaggerated expression of the invasive nature of nor-
mal trophoblastic tissue which did not assume the charac-
teristics of a malignant tumor. Twigg's et al, described a
patient with trophoblastic pseudotumor which was pro-
gressive and fatal in 1981 [2]. Scully and Young in 1981
described additional 14 cases of which two died from
metastatic disease [3].
Pathologically, the tumor is characterized by mononu-
clear intermediate trophoblastic cells with occasional
multinuclear intermediate trophoblastic cells and occa-
sional multinuclear giant cell which infiltrate both myo-
metrium and blood vessels [4]. Immunohistochemical
staining reveals many prolactin cells and few gonadotro-
pin producing ones. Thus gonadotropin levels may be
normal to elevated [5].
The etiology, epidemiology and risk-factors of PSTT are
poorly understood. Presenting symptoms generally
include irregular bleeding or amenorrhea and rarely neph-
rotic syndrome, sepsis, and erythrocytosis [6], or the met-
astatic sites may be the presenting symptoms. PSTT
presents with metastases in about 10% of the cases [7] and
metastases develop in an additional 10% during follow-
up [8].
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Although the majority of patients with non metastatic
PSTT are cured by hysterectomy, a number of cases require
aggressive treatment with chemotherapy and/or radiation.
This paper presents one case of PSTT treated by combined
treatment modalities. Hysterectomy was performed in
this case at a time when the exact diagnosis was not
apparent.
We also reviewed the literature for the different strategies
in treatment of the metastatic disease.
Case Presentation
In Sep. 1994, a 27-year-old woman (gravida 3, para 3) was
referred to Gynecology Oncology Unit in Vali-e-Asr Hos-
pital, Tehran, Iran. Her previous pregnancy was termi-
nated at 40 weeks, with vaginal delivery in May 1991.
After a few months of abnormal uterine bleeding, she
underwent dilatation and curettage and then a total
abdominal hysterectomy (2 months before referral). His-
tology of the resected specimen revealed
choriocarcinoma.
Upon her first visit to our clinic, she was in respiratory dis-
tress, and had cough with bloody sputum. Physical exam-
ination revealed no abnormal finding except wheezing.
Chest X-ray and computerized tomographic (CT) scan
showed multiple metastatic nodules in both lungs paren-
chyma (Figure 1). Abdominal and pelvic CT was normal.
Histology was reviewed by two expert pathologists in our
center, and PSTT was confirmed (Figure 2). Serum β -hCG
level was 210 mIU/ml. Serial serum β -hCG ranged
between 170 – 250, and increased after 3 courses of com-
bination chemotherapy with methotrexate, actinomycin
and cyclophosphamide.
Three years later, in november 1994, the patient was given
three cycles of EMA chemotherapy. However, due to pla-
teau titer of β -hCG the chemotherapy regimen was
changed to EMA-CE. Reassessment of staging work-up
was performed using pelvic ultrasonography that revealed
a hypoechoic mass in right ovary (42 mm). At the end of
six courses of EMA-CE chemotherapy, serum β -hCG
remained at 50 mIu/ml.
In May 1995, patient underwent laparotomy and right
oophrectomy one month following which the serum β -
hCG was negative. Patient is on regular follow-up (clinical
exam, β -hCG tests, pelvic and abdominal sonography and
chest CT) and has shown no signs of local or systemic
recurrence.
Discussion
PSTT is a rare form of GTD with unpredictable malignant
potential and highly variable clinical course [9]. It could
also present as a fulminant metastatic disease, resistant to
conventional treating modalities. PSTT accounts for 3.1/
1000 to 2/100 of all trophoblastic diseases [10,11]. Rate
of PSTT to choriocarcinoma has been reported to be 1/
138 [10]. The disease is usually seen in young women,
although cases have been reported in post-menopausal
women as well. The mean age at diagnosis is 31 to 33
years, and it can appear following any type of pregnancy
[10-12]. The antecedent pregnancy is a full term normal in
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53% of the cases [11,12], or a molar pregnancy seen in
21% of the cases [11,13]. The mean interval from the last
pregnancy and diagnosis of PSTT can vary from several
weeks up to 15 years [14].
Unlike choriocarcinoma, the level of serum β -hCG in
PSTT correlate neither with tumor burden, nor with the
malignant behavior. Thus β -hCG appears to have no pre-
dictive value and the disease may still progress even if lev-
els are not raised [14,23]. The range of serum β -hCG
concentrations at diagnosis in 79% of the patients is
below 1000 and in 58% lower than 500 [11].
In NETDC report, most patients (12 from 13 patients) had
β -hCG levels under 500 mIU/ml [12]. PSTT clearly
present a wide spectrum of clinical course. The most fre-
quent presenting symptom is vaginal bleeding (79%)
[11]. Ninty-two percent of Feltmate series presented with
amenorrhea or abnormal bleeding [12].
Outcome of PSTT as reported in literature is highly varia-
ble [9]. All cases of metastasis to vital organs, such as the
brain, result in mortality despite all forms of treatment.
PSTT is usually confined to uterus at the time of diagnosis.
In cases with distant spread of disease, metastases pre-
dominantly occur in the vagina and in lung as in our case.
Brain metastases have been detected in more than half of
PSTT patients [17,18]. Lung metastases have been
reported in nearly one third of the patients in Charing
Photomicrograph showing proliferating intermediate trophoblast with scares cytotophoblastic and systrophoblastic elements Figure 2
Photomicrograph showing proliferating intermediate trophoblast with scares cytotophoblastic and systrophoblastic elementsWorld Journal of Surgical Oncology 2005, 3:34 http://www.wjso.com/content/3/1/34
Page 4 of 4
(page number not for citation purposes)
Cross series [11]. In this series all the seven deaths in
patients with lung metastasis occurred in patients that pre-
sented 4 years or more after last pregnancy [11].
Extrauterine spread of the disease appears to be the most
useful prognostic factor for progression [19,20]. The inter-
val from the last known antecedent pregnancy appears to
be a second major prognostic variable in PSTT. In a mul-
tivariate analysis, the risk for unfavorable behavior of the
disease increased considerably with the length of this
interval [9,21]. Diagnosis less than 2 years from the ante-
cedent pregnancy, and the disease localized to the uterus
are associated with better outcome [9,11]. How et al,
found that likelihood for fatal outcome was 14 times
higher if the mitotic count was well above 5 [20].
In contrast to choriocarcinoma, PSTT is relatively resistant
to chemotherapy. Consequently surgery is the mainstay of
treatment. In most series more than one treatment modal-
ities have been used [9,11,14,19].
Conservative surgery in form of dilatation and curettage is
justified only if the fertility is to be preserved [22]. Further,
as PSTT is generally resistant to chemotherapy, there are
only few long term survivors, with metastatic PSTT despite
intensive multimodal therapy [9,23]. Local uterine resec-
tion may be considered in such patients and in those who
wants to retain fertility. When local resection is consid-
ered, ultrasound, MRI, and/or PET scan may identify the
site of residual tumor.
In other cases, hysterectomy followed by adjuvant chem-
otherapy is primary treatment- chemotherapy within one
week of hysterectomy, results in lower recurrence rates
[14]. The most recent data from different centers, suggest
that EMA/EP is the most effective treatment for metastatic
or recurrent PSTT [9].
Conclusion
PSTT is a disorder of uncertain outcome, some of the
patients do well while others have poor outcome. Com-
bined treatment have been reported in 26% – 55% of the
cases. Second look surgery, and multiple courses of com-
bined chemotherapy may be necessary for remission.
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